$NPCE
Neuropace Inc Stock $npce

$npce Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000152828721000018 Filed on November 10, 2021

Income Statement

Concept	2021 Q4	2021 Q3
Revenue	$11.00M	$10.34M
YoY Change		-19.04%
Cost Of Revenue	$2.921M	$2.832M
YoY Change		-11.39%
Gross Profit	$8.076M	$7.507M
YoY Change		-21.6%
Gross Profit Margin	73.44%	72.61%
Selling, General & Admin	$11.75M	$9.421M
YoY Change		33.63%
% of Gross Profit	145.44%	125.5%
Research & Development	$5.345M	$4.329M
YoY Change		17.29%
% of Gross Profit	66.18%	57.67%
Depreciation & Amortization	$79.00K	$100.0K
YoY Change		0.0%
% of Gross Profit	0.98%	1.33%
Operating Expenses	$17.09M	$13.75M
YoY Change		28.01%
Operating Profit	-$9.015M	-$6.243M
YoY Change		435.42%
Interest Expense	-$1.414M	$1.826M
YoY Change		-34.6%
% of Operating Profit
Other Income/Expense, Net	-$264.0K	-$14.00K
YoY Change		-91.67%
Pretax Income	-$10.69M	-$8.083M
YoY Change		95.71%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$10.69M	-$8.083M
YoY Change		95.9%
Net Earnings / Revenue	-97.24%	-78.18%
Basic Earnings Per Share		-$0.34
Diluted Earnings Per Share	-$441.0K	-$0.34
COMMON SHARES
Basic Shares Outstanding	24.31M shares	24.10M shares
Diluted Shares Outstanding		24.10M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.6M	$123.3M	$38.08M
YoY Change	203.54%
Cash & Equivalents	$19.19M	$26.63M	$26.39M
Short-Term Investments	$96.40M	$96.70M	$11.69M
Other Short-Term Assets	$2.319M	$3.383M
YoY Change
Inventory	$7.822M	$7.162M	$6.909M
Prepaid Expenses
Receivables	$7.091M	$6.611M	$8.395M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$132.8M	$140.5M	$54.56M
YoY Change	143.42%
LONG-TERM ASSETS
Property, Plant & Equipment	$603.0K	$624.0K	$515.0K
YoY Change	17.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$21.00K	$21.00K	$23.00K
YoY Change	-8.7%
Total Long-Term Assets	$746.0K	$767.0K	$1.388M
YoY Change	-46.25%
TOTAL ASSETS
Total Short-Term Assets	$132.8M	$140.5M	$54.56M
Total Long-Term Assets	$746.0K	$767.0K	$1.388M
Total Assets	$133.6M	$141.3M	$55.95M
YoY Change	138.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.378M	$1.254M	$949.0K
YoY Change	45.21%
Accrued Expenses	$7.923M	$7.420M	$6.603M
YoY Change	19.99%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$2.043M
YoY Change	-100.0%
Total Short-Term Liabilities	$9.301M	$8.674M	$9.595M
YoY Change	-3.06%
LONG-TERM LIABILITIES
Long-Term Debt	$49.85M	$49.58M	$50.82M
YoY Change	-1.92%
Other Long-Term Liabilities	$0.00	$248.0K	$274.0K
YoY Change	-100.0%
Total Long-Term Liabilities	$49.85M	$49.83M	$51.10M
YoY Change	-2.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.301M	$8.674M	$9.595M
Total Long-Term Liabilities	$49.85M	$49.83M	$51.10M
Total Liabilities	$60.06M	$59.55M	$62.36M
YoY Change	-3.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$423.8M	-$413.1M	-$387.7M
YoY Change	9.31%
Common Stock	$24.00K	$24.00K	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$73.50M	$81.71M	-$147.8M
YoY Change
Total Liabilities & Shareholders Equity	$133.6M	$141.3M	$55.95M
YoY Change	138.72%

Cashflow Statement

Concept	2021 Q4	2021 Q3
OPERATING ACTIVITIES
Net Income	-$10.69M	-$8.083M
YoY Change		95.9%
Depreciation, Depletion And Amortization	$79.00K	$100.0K
YoY Change		0.0%
Cash From Operating Activities	-$8.203M	-$4.424M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures	-$154.0K	-$178.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$12.00K
YoY Change
Cash From Investing Activities	-$154.0K	-$190.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	911.0K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	-8.203M	-4.424M
Cash From Investing Activities	-154.0K	-190.0K
Cash From Financing Activities	911.0K	0.000
Net Change In Cash	-7.446M	-4.614M
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$8.203M	-$4.424M
Capital Expenditures	-$154.0K	-$178.0K
Free Cash Flow	-$8.049M	-$4.246M
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Central Index Key EntityCentralIndexKey	0001528287
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2020Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0100
CY2021Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.3846
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40337
	dei	Entity Registrant Name EntityRegistrantName	NEUROPACE, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-3550230
	dei	Entity Address Address Line1 EntityAddressAddressLine1	455 N. Bernardo Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	Mountain View
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94043
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	237-2700
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	NPCE
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	24314002	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26633000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26390000	USD
CY2020Q2	npce	Operating Lease Percent Rental Payment Deferred OperatingLeasePercentRentalPaymentDeferred	0.500
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	96701000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	11689000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6611000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8395000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	7162000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6909000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3383000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1179000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	140490000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	54562000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	515000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	366000	USD
CY2021Q3	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	484000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	23000	USD
CY2021Q3	us-gaap	Assets Assets	141257000	USD
CY2020Q4	us-gaap	Assets Assets	55950000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1254000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	949000	USD
CY2021Q3	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	7420000	USD
CY2020Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	6603000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2043000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8674000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9595000	USD
CY2021Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1041000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1301000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49582000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50821000	USD
CY2021Q3	npce	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	0	USD
CY2020Q4	npce	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	369000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	248000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	274000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	59545000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	62360000	USD
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	60757386	shares
CY2021Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2021Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2021Q3	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	0	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	227755000	USD
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	74636348	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24307898	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24307898	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	314096	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	314096	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	494733000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	239826000	USD
CY2021Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	33000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	33000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-413078000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-387691000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	81712000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-147832000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	141257000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55950000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10339000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12771000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34186000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30386000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2832000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3196000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8827000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8333000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	7507000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	9575000	USD
	us-gaap	Gross Profit GrossProfit	25359000	USD
	us-gaap	Research And Development Arrangement With Federal Government Costs Incurred Net ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet	57000	USD
	us-gaap	Gross Profit GrossProfit	22053000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4329000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3691000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12866000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11776000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9421000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7050000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27215000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20347000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	13750000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	10741000	USD
	us-gaap	Operating Expenses OperatingExpenses	40081000	USD
	us-gaap	Operating Expenses OperatingExpenses	32123000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6243000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1166000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14722000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10070000	USD
CY2021Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
CY2020Q3	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	203000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	0	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	1258000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	1826000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	2792000	USD
	us-gaap	Interest Expense InterestExpense	5548000	USD
	us-gaap	Interest Expense InterestExpense	9603000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-168000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5117000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	13000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8083000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4126000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25387000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	22000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19660000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8061000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4122000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25387000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19660000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.26
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-96.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-96.02
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24101399	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24101399	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202408	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202408	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14061958	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14061958	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202382	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202382	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-147832000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-8810000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	202000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-156436000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8494000	USD
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000	USD
CY2021Q2	npce	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock Value ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockValue	147028000	USD
CY2021Q2	npce	Sale Of Stock Underwriting Discount Commissions And Deferred Offering Costs SaleOfStockUnderwritingDiscountCommissionsAndDeferredOfferingCosts	11813000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	105487000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	4000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-4000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1103000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	88666000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8083000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	22000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1107000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	81712000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-129350000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-6741000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-41000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	301000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-135825000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-8793000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	37000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	290000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-144291000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4126000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	4000	USD
CY2020Q3	npce	Conversion Of Convertible Notes Into Redeemable Convertible Preferred Stock Value ConversionOfConvertibleNotesIntoRedeemableConvertiblePreferredStockValue	4148000	USD
CY2020Q3	npce	Reduction Of Redeemable Convertible Preferred Stock Liquidation Value ReductionOfRedeemableConvertiblePreferredStockLiquidationValue	228000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	301000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-143736000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25387000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19660000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2412000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	892000	USD
	us-gaap	Depreciation Depreciation	217000	USD
	us-gaap	Depreciation Depreciation	241000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	200000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5337000	USD
	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	608000	USD
	npce	Increase Decrease In Non Cash Interest Expense IncreaseDecreaseInNonCashInterestExpense	1350000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	-4081000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	185000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	546000	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	0	USD
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-15000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	5236000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-149000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-182000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1784000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2038000	USD
	us-gaap	Depreciation Depreciation	200000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	438000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-896000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2227000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-212000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	259000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	45000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1296000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	933000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	317000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-519000	USD
	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-223000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16374000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15185000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	230000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	USD
CY2020Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	300000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	6300000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	85012000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	7005000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-85242000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-721000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	109089000	USD
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3392000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	31696000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	4090000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	42121000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	0	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	54047000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	122000	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	854000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	11867000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	12514000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101615000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55288000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	39382000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26756000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4123000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26755000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43505000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26633000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43139000	USD
CY2020Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	366000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26755000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43505000	USD
	us-gaap	Interest Paid Net InterestPaidNet	4740000	USD
	us-gaap	Interest Paid Net InterestPaidNet	2813000	USD
	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	4000	USD
	npce	Increase Decrease In Accrued Liabilities Early Exercise Of Options IncreaseDecreaseInAccruedLiabilitiesEarlyExerciseOfOptions	0	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	97000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	34113000	USD
	npce	Extinguishment Of Derivative Liability ExtinguishmentOfDerivativeLiability	0	USD
	npce	Extinguishment Of Derivative Liability ExtinguishmentOfDerivativeLiability	6239000	USD
	npce	Class Of Warrant Or Right Warrants Issued ClassOfWarrantOrRightWarrantsIssued	0	USD
	npce	Class Of Warrant Or Right Warrants Issued ClassOfWarrantOrRightWarrantsIssued	550000	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	94000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-413100000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16400000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15200000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	123300000	USD
CY2021Q2	npce	Debt Instrument Covenant Minimum Annual Net Revenue DebtInstrumentCovenantMinimumAnnualNetRevenue	43000000	USD
CY2021Q2	npce	Debt Instrument Covenant Minimum Cash And Cash Equivalents Required After Completion Of Ipo DebtInstrumentCovenantMinimumCashAndCashEquivalentsRequiredAfterCompletionOfIPO	5000000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim condensed financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. The Company uses significant judgment when making estimates related to the valuation of its common stock and related stock-based compensation, the valuation of deferred tax assets and related valuation allowances, provision for excess and obsolete inventories, the valuation of derivative financial instruments and redeemable </span></div>convertible preferred stock warrant liability. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk, and Other Risks and Uncertainties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash and cash equivalents, short-term investments and accounts receivable to the extent of the amounts recorded on the balance sheet. The Company’s cash is invested in one major financial institution in the United States. Deposits in this financial institution may exceed federally insured limits. The Company’s cash equivalents are invested in money market funds.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable are due from a variety of health care organizations in the United States. For the three and nine months ended September 30, 2021 and 2020, there were no customers that represented 10% or more of revenue. As of September 30, 2021 and December 31, 2020, no customer represented 10% or more of the Company’s accounts receivable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to certain risks, including that its devices may not be approved or cleared or continue to be approved or cleared for marketing by governmental authorities or be successfully marketed for expanded indications. There can be no assurance that the Company’s products will achieve widespread adoption in the marketplace, nor can there be any assurance that existing devices or any future devices can be developed or manufactured at an acceptable cost and speed and with appropriate performance characteristics. The Company is also subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, dependence on healthcare providers to prescribe initial implants and replacements, dependence upon third-party payors to provide adequate coverage and reimbursement, dependence on key personnel, single-source suppliers and vendors in connection with the manufacture of its products, concentration of Level 4 CECs and epileptologists, obtaining, maintaining, protecting, enforcing, and defending intellectual property rights and proprietary technology, product liability claims, legal proceedings, and compliance with government regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s medical devices require approvals or clearances from the U.S. Food and Drug Administration, or the FDA, or international regulatory agencies. In addition, in order to continue the Company’s operations, compliance with various federal and state laws is required. If approvals or clearances were withdrawn by the FDA for the Company’s current products or if such approvals or clearances were denied or delayed for future products, product updates, or expanded indications for use, it would have a material adverse impact on the Company.</span></div>
CY2020Q4	us-gaap	Deferred Costs DeferredCosts	500000	USD
CY2021Q3	us-gaap	Deferred Costs DeferredCosts	0	USD
CY2021Q2	npce	Research And Development Arrangement With Federal Government Term ResearchAndDevelopmentArrangementWithFederalGovernmentTerm	P5Y
CY2021Q2	npce	Research And Development Arrangement With Federal Government Total Estimated Cost ResearchAndDevelopmentArrangementWithFederalGovernmentTotalEstimatedCost	9300000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	800000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	25312000	USD
CY2021Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	96701000	USD
CY2021Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	122013000	USD
CY2021Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	5062000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	11689000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	16751000	USD
CY2020Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	369000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	369000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	96668000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	11656000	USD
CY2021Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	33000	USD
CY2021Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	96701000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	11689000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	1596000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1721000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1467000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1487000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4099000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3701000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	7162000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6909000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9002000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8676000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8378000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8161000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	624000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	515000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	100000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	100000	USD
	us-gaap	Depreciation Depreciation	200000	USD
CY2020Q4	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	6603000	USD
CY2021Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5618000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4565000	USD
CY2021Q3	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	340000	USD
CY2020Q4	npce	Accrued Inventory Liability Current AccruedInventoryLiabilityCurrent	636000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	164000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	279000	USD
CY2021Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	407000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	666000	USD
CY2021Q3	npce	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	0	USD
CY2020Q4	npce	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	107000	USD
CY2021Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	891000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	USD
CY2021Q3	npce	Accrued And Employee Related Liabilities Current AccruedAndEmployeeRelatedLiabilitiesCurrent	7420000	USD
CY2018Q2	npce	Operating Lease Renewal Term OperatingLeaseRenewalTerm	P5Y
CY2021Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	8882000	USD
CY2020Q4	npce	Operating Lease Deferred Rent Interest Rate Annual Rate OperatingLeaseDeferredRentInterestRateAnnualRate	0.080
CY2021Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
CY2020Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	700000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2000000	USD
CY2021Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	1400000	USD
CY2020Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	2000000	USD
CY2021Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	777000	USD
CY2021Q3	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	3172000	USD
CY2021Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	3267000	USD
CY2021Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1666000	USD
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.125
CY2021Q3	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.1566
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	60757386	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	16614178	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	141422000	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	227755000	USD
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	USD
	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	0	USD
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6935379	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20615380	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	818889	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2835265	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.03
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M25D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	2900000	shares
	npce	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Retired During Period ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesRetiredDuringPeriod	485581	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	577144	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	577144	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.35
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	265498	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	57090	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	57090	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.64
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2713254	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3089821	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y25D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	869981	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.48
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y9M29D
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3089821	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.50
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P9Y25D
CY2021Q3	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	192741	shares
CY2020Q4	npce	Share Based Compensation Arrangement By Share Based Payment Award Options Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSubjectToRepurchase	30802	shares
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.85
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	13746	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	23.79
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1107000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	301000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2412000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	892000	USD
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1107000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	301000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2412000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	892000	USD
CY2021Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	17300000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y6M
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-8083000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-4126000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-25387000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-19660000	USD
CY2021Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2020Q3	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	228000	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	228000	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8083000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3898000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25387000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19432000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24101399	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24101399	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202408	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202408	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14061958	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14061958	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	202382	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	202382	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.26
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.81
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-96.02
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-96.02
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3892380	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17133911	shares

Files In Submission

Name	View Source	Status
0001528287-21-000018-index-headers.html	Edgar Link	pending
0001528287-21-000018-index.html	Edgar Link	pending
0001528287-21-000018.txt	Edgar Link	pending
0001528287-21-000018-xbrl.zip	Edgar Link	pending
exhibit311-certificationss.htm	Edgar Link	pending
exhibit312certificationsse.htm	Edgar Link	pending
exhibit321certificationsse.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
npce-20210930.htm	Edgar Link	pending
npce-20210930.xsd	Edgar Link	pending
npce-20210930_cal.xml	Edgar Link	unprocessable
npce-20210930_def.xml	Edgar Link	unprocessable
npce-20210930_htm.xml	Edgar Link	completed
npce-20210930_lab.xml	Edgar Link	unprocessable
npce-20210930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NPCE
Neuropace Inc Stock $npce

2021 Q4 Form 10-Q Financial Statement

#000152828721000018 Filed on November 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE Neuropace Inc Stock $npce

2021 Q4 Form 10-Q Financial Statement

#000152828721000018 Filed on November 10, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NPCE
Neuropace Inc Stock $npce